
品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

商品描述
Human Anti-Infliximab, clone AbD17841_hIgG1 is an anti-idiotypic antibody that specifically recognizes the infliximab monoclonal antibody and inhibits the binding of infliximab to its target. It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.Human anti Infliximab, clone AbD17841_hIgG1 is a fully human antibody and may be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera. In the HRP-conjugated format, clone AbD17841_IgG1 is suitable as a detection antibody in pharmacokinetic (PK) assays.Infliximab (branded as Remicade) is a chimeric monoclonal antibody drug (IgG1/kappa) that has been approved for treatment of psoriasis, Crohn"s disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis.Infliximab is directed against Tumor Necrosis Factor Alpha (TNFα) and acts by blocking the binding of this cytokine to its receptors. Infliximab also induces apoptosis of TNFα expressing T-lymphocytes.View a summary of all Anti-Infliximab Antibodies.
Product Details
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
- Product Form
- Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- Preservative Stabilisers
- 0.01% Thiomersal
- Immunogen
- Infliximab
- Affinity
- The monovalent intrinsic affinity of this antibody was measured as KD=1.8 nM by real time, label-free molecular interaction analysis on immobilized Infliximab.
- Approx. Protein Concentrations
- Total protein concentration 0.1 mg/ml
- Approx. Protein Concentrations
- Pack Size: 0.1 mgAntibody concentration 0.5 mg/mlPack Size: 1 mgAntibody concentration 1.0 mg/ml
Storage Information
- Storage
- Store at -70oC.Storage in frost-free freezers is not recommended.This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
- Storage
- Store at +4oC or at -20oC if preferred.Storage in frost-free freezers is not recommended.This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Guarantee
- 12 months from date of despatch
- Guarantee
- 12 months from date of despatch
More Information
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade® is a registered trademark of Janssen Biotech Inc. Inflectra® is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS™ is a trademark of Merck Sharp & Dohme Corp.
- Acknowledgements
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents.This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- Regulatory
- For research purposes only
Applications of Infliximab antibody
Application Name | Verified | Min Dilution | Max Dilution |
---|---|---|---|
ELISA | 1/100 | 1/1000 | |
ELISA |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in theHuCAL Antibodies Technical Manual
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in theHuCAL Antibodies Technical Manual
- ELISA
- This product may be used in as a detection antibody in an Infliximab bridging ELISA together with HCA212 as the capture reagent. Protocol: PK bridging ELISA to measure free drug
- ELISA
- This product may be used in a direct ELISA, as a bridging antibody in ADA assays or as a detection antibody in an Infliximab bridging ELISA when conjugated to HRP together with HCA212 as the capture reagent.Protocol: PK bridging ELISA to measure free drugProtocol: ADA bridging ELISA
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Useful Reagents Available
Description | Product Code | Applications | Pack Size | List Price | Quantity |
---|---|---|---|---|---|
Human anti Infliximab | HCA212 | E | 0.1 mg | ![]() | |
Human anti Infliximab | HCA214 | E | 0.1 mg | ![]() | |
Human anti Infliximab | HCA215 | E | 0.1 mg | ![]() | |
Human anti Infliximab | HCA216 | E | 0.1 mg | ![]() | |
Recombinant Human TNF Alpha | PHP051 | E FN WB | 50 µg | ![]() | |
Hispec Assay Diluent | BUF049A | E IY | 50 ml | ||
Human anti Infliximab | HCA212 | E | 0.1 mg | ![]() | |
Human anti Infliximab | HCA214 | E | 0.1 mg | ![]() | |
Human anti Infliximab | HCA215 | E | 0.1 mg | ![]() | |
Human anti Infliximab | HCA216 | E | 0.1 mg | ![]() | |
LYNX Rapid HRP Antibody Conjugation Kit | LNK002P | CJ | 3 Conjugations For 400µg Antibody | ||
Mouse anti Human IgG (Fc) CH2 Domain:HRP | MCA647P | C* E | 0.2 mg | ![]() | |
Recombinant Human TNF Alpha | PHP051 | E FN WB | 50 µg | ![]() |
Product Specific References
References for Infliximab antibody
- Hernández-Breijo, B. et al. (2015) Quantification of the concentration of antibodies against Infliximab in human serum using a pure antibody as calibrator.10th Congress of ECCO, Barcelona P020
- Hernández-Breijo, B. et al. (2016) Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.Biochem Pharmacol. Sep 21. pii: S0006-2952(16)30302-1. [Epub ahead of print]
View more products with Infliximab specificity